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OBJECTIVES: Although HTA is well established in healthcare systems like the Eng-
land & Wales National Health Service (NHS), it is increasingly used more formally
in developing countries such as Poland and Mexico. The objectives of this research
were to understand the drivers of decision-making and future trends in these HTA
systems in relation to market access for pharmaceuticals. METHODS: Secondary
research and structured telephone interviews with 12 key stakeholders in Poland
and Mexico was carried out. The research evaluated trends in the following aspects
of the systems: impact of HTA in final reimbursement decisions, positioning of HTA
in the healthcare system and future trends. A comparison of the impact of HTA in
Mexico and Poland was then made on a rating scale devised to account for these
influencing factors. RESULTS: HTA in Mexico is positioned within a highly decen-
tralised healthcare system, although its Federal Cuadro Básico is important in
determining price and access for pharmaceuticals. HTA appraisals although
mostly conducted by IMSS (60% of reimbursement) are also used by the other
reimbursing institutions. The Polish HTA body, AHTAPol, works closely with the
reimbursement process at the central level, but its ultimate influence on price and
reimbursement is moderate; the majority of respondents (n8) regarded HTA as
more of a negotiating tool, as decision-making balances multiple diverse interests.
CONCLUSIONS: HTA is seen to impact the Polish system, despite being centralised
to a lesser extent than Mexico, which has a decentralised health system and a
significant private sector. In addition to HTA, historical development of the health
care system, external influences and financial resources are equally important
drivers of access decisions.
PHP37
CROSS-CONTINENTAL COMPARISON OF HTA EVOLUTION IN EMERGING
MARKETS: BRAZIL, INDIA AND POLAND
Kirpekar S, Shankland B, Dummett H
Double Helix Consulting, London, UK
OBJECTIVES: Despite universal healthcare being the common motto, healthcare
systems in developing economies around the world have developed to varying
extents. HTA as a concept has evolved particularly in Western European markets to
ensure equity and equality of healthcare provision. Understanding the status of
HTA evolution and impact on reimbursement decisions is expected to have lessons
to be learnt for countries like India where non-evolution of HTA is seen.METHODS:
Secondary research to understand the reimbursement systems publicly available
information about recent reimbursement decisions was done. Primary research
involved discussions with decision makers in important reimbursement bodies.
Eight in-depth interviews were conducted covering individuals from a variety of
backgrounds. Information was collected under headings covering current drivers,
historical influences, existing issues, reasons for evolution / non-evolution of HTA
and expected changes. Data was analysed qualitatively to develop results.
RESULTS: Broadly, HTA was seen to be non-evolved in India. Majority of the market
being out-of-pocket is considered the key driver where both industry and doctors
are thought to generally oppose any formal technology appraisals (n6). At the
other end of the spectrum, despite having a multi-payer reimbursement system,
Brazil was seen to be using HTA as a tool for reimbursement decisions widely (n6).
Poland however, despite having a well-developed HTA system was seen to use HTA
more as a negotiation tool than for reimbursement decisions (n4).
CONCLUSIONS: A tri-directional comparison of HTA systems and their involve-
ment in the reimbursement system showed that the reasons behind the varying
level of HTA influence can be attributed somewhat to the history of the healthcare
systems. There are lessons to be learned for Poland, which is a centralised system
from other centralised systems like England and for India from Brazil. In-depth
research involving lessons from Brazil for India is warranted.
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OBJECTIVES: Analyze the health technology assessment (HTA) scenario and pro-
cess to Medical Devices (MD) in Latin American and discuss the appropriateness of
the present process. METHODS: search in Latin American and Caribbean Health
Sciences Literature (LILACS), PubMed, gray literature and internet search.
RESULTS:MD and drugs differ from their concept to usage, therefore it is important
to note that is not always possible to apply the same HTA processes to both cate-
gories. In the research, we found in Latin America 12 countries with significant HTA
initiatives and the majority emerged in the past decade. In total, 4 countries with
published economic evaluation guidelines, 17 HTA committees and groups, 6 IS-
POR chapters, the Pan American Health Organization (PAHO) HTA initiative and
Mercosur HT special group. The expertise with HTA applied to drugs seems to be
higher than HTA applied to MD across Latin America and this was observed in
appraisals published by the main HTA agencies. Important to note the almost non
existence of specific HTA guidelines to MD among HTA agencies, groups and
committees. CONCLUSIONS: The methodological validity should consider a
broader source of evidence to evaluate the efficacy of certain MD or for certain
clinical indications or settings. Patient and/or investigator blinding is impractical
or impossible for many MD and most surgical procedures. Observational studies
should be considered as a relevant source of data for HTA, often randomized clin-
ical trials do not provide real life data and are not always feasible technically and
ethically for devices. MD has a shorter life cycle and it is not compatible with HTA
cycles which can vary from 6 months to 4 years for a sound assessment. HTA
agencies, committees and groups in Latin America must recognize the medical
devices specificities and its market dynamics and incorporate to existing guide-
lines a process adequate to this category.
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OBJECTIVES: HTA is at different stages of development across Latin America, from
Brazil’s highly developed system at one extreme to Venezuela at the other, despite
the existence of substantial local expertise. This study attempts to explain these
disparities. METHODS: A total of 20 HTA reviewers and academic health econo-
mists were interviewed across Brazil, Argentina, Mexico, Chile and Venezuela to
understand the parameters of the HTA system, the importance of different stake-
holders within the process and the decisions influenced by HTA. RESULTS: HTA
systems within Latin America exist at all stages of the HTA development contin-
uum, although they are better developed than in many other developing countries.
At one end sits a multi-payer, universal health system Brazil in which demonstra-
tion of cost-effectiveness is considered highly important for central funding deci-
sions. At the other extreme sit Chile and Venezuela in which no formal role for HTA
yet exists, although the speed and direction of HTA development in these two
countries is likely to differ. In between sits Argentina, where HTA capability is
advanced but operating within a fragmented health system. CONCLUSIONS: HTA
is developing rapidly within the markets surveyed suggesting that private actors
would be rational to invest in local expertise. However, despite formalisation, cost-
effectiveness may remain only one of many decision factors. Understanding the
nuances of where HTA sits in the reimbursement system and how it is applied in
practice in each market is essential for maximising favourable outcomes for sup-
pliers and providers alike.
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OBJECTIVES: In order to implement strategies that promote an efficient use of
public health services and grant more access opportunities to the population, irre-
spective of their insurance status, estimate the volume and type of hospital care
services provided by the Ministry of Health (MoH) to patients who have social
security or private health insurance. METHODS: The exercise was made though an
analysis by ICD-10 of the Hospital Discharge Automated System, which concen-
trates hospital activity from over 600 hospitals belonging to MoH, between January
2006 and August 2010. Patients having a social security scheme (IMSS, ISSSTE,
PEMEX, SEDENA y SEMAR) or private health insurance were analyzed. RESULTS: A
total of 11.9 million of attentions were recorded in the analyzed period, 2.2 on
average per year, of which, 40 thousand (1.7%) corresponded to patients who be-
long to a social security institution or private health insurance. Among the insti-
tutions of origin, IMSS led the list with 45% of the total, followed by ISSSTE with 26%
and private insurances with 20%. By ICD-10 chapter, Pregnancy, childbirth and puer-
perium (O00-O99) was the most demanded, with 24.5% of the total attentions. In the
analysis by state, about 50% of cases came from five to seven states; in 2010 the
state of Jalisco led the list with 14.5% of the total, followed by the states of Tama-
ulipas and Mexico, with about 7% each. Considering all the analyzed period, the
most common intervention was Single spontaneous delivery (O80), (41% in 2010).
CONCLUSIONS: Quantifying the MoH health care demand coming from social and
private insured population and its evolution will permit the definition of better
exchange planning strategies and guarantee its appropriate financial compensa-
tion. Besides analyze the exchange volume and their characteristics; establishing
fees and agreements is needed to implement reimbursement systems between
public sector institutions.
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OBJECTIVES: The study evaluated recent data related to real impact measurement
of HPV prevention or cervical oncologic diseases related to HPV infection available
from publications in the EU member states. The main idea was to find out whether
there is any prerequisite to evaluate the effectiveness of the preventive HPV vac-
cination based on the existing data and standard approaches within the EU in the
future in an observational study. The second goal was to define these prerequisites
in order to use them for “good practice.” METHODS: The systematic review of
PUBMED, EMBASE and CENTRAL extended to official websites of public health in-
stitutions officially published data was used. The goal was to find all papers on
HPV/cervical cancer epidemiology, screening, and prevention published in years
2009- 2011, related to EU member states. Only studies related to countries from the
European Union were taken into account. All relevant data were extracted and
compared. Population size was derived from Eurostat. Based on this data we cre-
ated the principles for evaluation of HPV screening and monitoring of quality
indicators. RESULTS:Out of 27 EU countries, only 2 countries (Denmark and United
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